COVID-19 Treatments: University of California Introduces Aeronabs-An Inhaler That Releases Highly Potent Antiviral Nanobodies Against The SARS-COV-2

COVID-19 Treatments: University Of California-San Francisco scientists have developed a novel approach to halting the spread of SARS-CoV-2 involving an aerosol formulation of nanobodies that are basically antiviral molecules that inhibit the virus.


 
The research and development  lead by graduate student Michael Schoof, along with a team of researchers engineered a completely synthetic, production-ready molecule that straitjackets the crucial SARS-CoV-2 machinery that allows the virus to infect our cells.
 
The research paper is published on a preprint server and is pending peer-review. https://www.biorxiv.org/content/10.1101/2020.08.08.238469v1
 
Accordingly based on experiments with live virus, these nanobodies are so far of the most potent SARS-CoV-2 antivirals yet discovered.
 
The research team tested an aerosol formulation, dubbed "AeroNabs" by the study team, and the emerged results were encouraging.
 
These nanobody molecules could be self-administered with a nasal spray or inhaler.
 
The study team says that used once a day, AeroNabs could provide powerful, reliable protection against SARS-CoV-2 until a vaccine becomes available.
 
The study team is in active discussions with commercial partners to ramp up manufacturing and clinical testing of AeroNabs. If these tests are successful, the scientists aim to make AeroNabs widely available as an inexpensive, over-the-counter medication to prevent and treat COVID-19.
 
AeroNAbs Co-inventor Dr Peter Walter, PhD, Professor of biochemistry and biophysics at UCSF and a Howard Hughes Medical Institute Investigator told Thailand Medical News, "Far more effective than wearable forms of personal protective equipment, we think of AeroNabs as a molecular form of PPE that could serve as an important stopgap until vaccines provide a more permanent solution to COVID-19.”
 
He added, “For those who cannot access or don't respond to SARS-CoV-2 vaccines. AeroNabs could be a more permanent line of defense against COVID-19.”
 
Schoof, a member of the Walter lab and an AeroNabs co-inventor also added,
"We assembled an incredible group of talented biochemists, cell biologists, virologists and structural biologists to get the project from start to finish in only a few months."
 
Although engineered entirely in the lab, AeroNabs were inspired by nanobodies, antibody-like immune proteins that naturally occur in llamas, camels and related animals. Since their discovery in a Belgian lab in the late 1980s, the distinctive properties of nanobodies have intrigued scientists worldwide.
 
Co-inventor Dr Aashish Manglik, MD, PhD, an Assistant Professor of pharmaceutical chemistry who frequently employs nanobodies as a tool in his research on the structure and function of proteins that send and receive signals across the cell's membrane explained, "Though they function much like the antibodies found in the human immune system, nanobodies offer a number of unique advantages for effective therapeutics against SARS-CoV-2.”
 < br /> He continued, “For example, nanobodies are an order of magnitude smaller than human antibodies, which makes them easier to manipulate and modify in the lab. Their small size and relatively simple structure also makes them significantly more stable than the antibodies of other mammals. Plus, unlike human antibodies, nanobodies can be easily and inexpensively mass-produced ie scientists insert the genes that contain the molecular blueprints to build nanobodies into E. coli or yeast, and transform these microbes into high-output nanobody factories. The same method has been used safely for decades to mass-produce insulin.”
 
He further added, "Nanobodies were just the starting point for us. Though appealing on their own, we thought we could improve upon them through protein engineering. This eventually led to the development of AeroNabs."
 
The SARS-CoV-2coronavirus relies on its so-called spike proteins to infect cells.
Interesting like a retractable tool, spikes can switch from a closed, inactive state to an open, active state. When any of a virus particle's approximately 25 spikes become active, that spike's three "receptor-binding domains," or RBDs, become exposed and are primed to attach to ACE2, a receptor found on human cells that line the lung and airway.
 
Utilizing a lock-and-key-like interaction between an ACE2 receptor and a spike RBD, the virus gains entry into the cell, where it then transforms its new host into a coronavirus manufacturer. The researchers believe that nanobodies could impede spike-ACE2 interactions and prevent the virus from infecting cells.
 
The study team analyzed in detail a recently developed library in Manglik's lab of over 2 billion synthetic nanobodies. After successive rounds of testing, during which they imposed increasingly stringent criteria to eliminate weak or ineffective candidates, the scientists ended up with 21 nanobodies that prevented a modified form of spike from interacting with ACE2.
 
Detailed experiments, including the use of cryo-electron microscopy to visualize the nanobody-spike interface, showed that the most potent nanobodies blocked spike-ACE2 interactions by strongly attaching themselves directly to the spike RBDs. These nanobodies function a bit like a sheath that covers the RBD "key" and prevents it from being inserted into an ACE2 "lock."
 
Using these findings in hand, the researchers still needed to demonstrate that these nanobodies could prevent the real virus from infecting cells.
 
Dr Veronica Rezelj, PhD, a virologist in the lab of Marco Vignuzzi, PhD, at Institut Pasteur in Paris, tested the three most promising nanobodies against live SARS-CoV-2, and found the nanobodies to be extraordinarily potent, preventing infection even at extremely low doses.
 
Significantly, the most potent of these nanobodies, however, not only acts as a sheath over RBDs, but also like a molecular mousetrap, clamping down on spike in its closed, inactive state, which adds an additional layer of protection against the spike-ACE2 interactions that lead to infection.
 
The study team then engineered this double-action nanobody in a number of ways to make it into an even more potent antiviral. In one set of experiments, they mutated every one of the amino-acid building blocks of the nanobody that contacts spike to discover two specific changes that yielded a 500-fold increase in potency.
 
In a series of experiments, the team engineered a molecular chain that could link three nanobodies together. As noted, each spike protein has three RBDs, any of which can attach to ACE2 to grant the virus entry into the cell. The linked triple nanobody devised by the researchers ensured that if one nanobody attaches itself to an RBD, the other two would attach to the remaining RBDs. They found that this triple nanobody is 200,000 times more potent than a single nanobody alone.
 
The results of both modifications, linking three of the powerful mutated nanobodies together, showed a highly potent antiviral product.”
 
It is this ultrapotent three-part nanobody construct that formed the foundation for AeroNabs.
 
The researchers in a final set of experiments put the three-part nanobodies through a series of stress tests, subjecting them to high temperatures, turning them into a shelf-stable powder, and making an aerosol.
 
Although each of these processes was highly damaging to most proteins, the nanobodies withstood them due to their inherent stability and there was no loss of antiviral potency in the aerosolized form, suggesting that AeroNabs are a potent SARS-CoV-2 antiviral that could be practical to administer via a shelf-stable inhaler or nasal spray.
 
Dr Manglik said, "We are not alone in thinking that AeroNabs are a remarkable technology. Our team is in ongoing discussions with potential commercial partners who are interested in manufacturing and distributing AeroNabs, and we hope to commence human trials soon. If AeroNabs prove as effective as we anticipate, they may help reshape the course of the pandemic worldwide."
 
The team is also shortly starting actual clinical trials on the developed treatment platform.
 
For more about COVID-19 Treatments, keep on logging to Thailand Medical News.